1 A serological assay to detect SARS-CoV-2 seroconversion in humans

- 2
- 3 Fatima Amanat^{1,2}, Daniel Stadlbauer¹, Shirin Strohmeier^{1,3}, Thi H.O. Nguyen⁴, Veronika Chromikova¹,
- 4 Meagan McMahon¹, Kaijun Jiang¹, Guha Asthagiri Arunkumar^{1,2}, Denise Jurczyszak^{1,2}, Jose Polanco^{1,5},
- 5 Maria Bermudez-Gonzalez¹, Giulio Kleiner¹, Teresa Aydillo¹, Lisa Miorin¹, Daniel Fierer⁶, Luz Amarilis
- 6 Lugo⁶, Erna Milunka Kojic⁶, Jonathan Stoever⁷, Sean T. H. Liu⁶, Charlotte Cunningham-Rundles⁸, Philip L.
- 7 Felgner⁹, Thomas Moran¹, Adolfo Garcia-Sastre^{1,10}, Daniel Caplivski¹¹, Allen Cheng¹², Katherine
- 8 Kedzierska⁴, Olli Vapalahti^{13,14,15}, Jussi M. Hepojoki^{13,16}, Viviana Simon^{1,6,10} and Florian Krammer^{1*}
- 9
- ¹Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ²Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ³Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
- ⁴Department of Microbiology & Immunology, University of Melbourne, The Peter Doherty Institute for
- 14 Infection & Immunity, Melbourne, Victoria, Australia
- ⁵Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,
 USA
- ⁶Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New
- 18 York, NY, USA
- ⁷Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, *New York, NY, USA*
- 21 ⁸Department of Pediatrics and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ⁹Department of Physiology & Biophysics, University of California, Irvine, CA, USA
- 23 ¹⁰Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA
- 24 ¹¹Travel Medicine Program, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New
- 25 York, NY, USA
- 26 ¹²School of Public Health and Preventive Medicine, Monash University; Infection Prevention and
- 27 Healthcare Epidemiology Unit, Alfred Health
- ¹³Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- 29 ¹⁴Veterinary Biosciences, Veterinary Faculty, University of Helsinki, Helsinki, Finland
- 30 ¹⁵Department of Virology and Immunology, Helsinki University Hospital (HUSLAB), Helsinki, Finland
- ¹⁶Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland
- 32
- 33 *To whom correspondence should be addressed: florian.krammer@mssm.edu
- 34
- 35

36 Abstract

- 37 SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019
- 38 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While
- 39 molecular assays to directly detect the viral genetic material are available for the diagnosis of acute
- 40 infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies. Here
- 41 we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using

42 recombinant antigens derived from the spike protein of SARS-CoV-2. Using negative control samples 43 representing pre-COVID 19 background immunity in the general adult population as well as samples 44 from COVID19 patients, we demonstrate that these assays are sensitive and specific, allowing for 45 screening and identification of COVID19 seroconverters using human plasma/serum as early as two days 46 post COVID19 symptoms onset. Importantly, these assays do not require handling of infectious virus, 47 can be adjusted to detect different antibody types and are amendable to scaling. Such serological assays 48 are of critical importance to determine seroprevalence in a given population, define previous exposure 49 and identify highly reactive human donors for the generation of convalescent serum as therapeutic. 50 Sensitive and specific identification of coronavirus SARS-Cov-2 antibody titers may, in the future, also 51 support screening of health care workers to identify those who are already immune and can be 52 deployed to care for infected patients minimizing the risk of viral spread to colleagues and other 53 patients.

54

55 Introduction

On December 31st, 2019 China reported first cases of atypical pneumonia in Wuhan, the capital of Hubei 56 province. The causative virus was found to be a betacoronavirus, closely related to the severe acute 57 58 respiratory syndrome coronavirus (SARS-CoV-1) from 2003 and similar to Sarbecoviruses isolated from 59 bats.^{1,2} It was therefore termed SARS-CoV-2 and the disease it causes was named COVID19 (COronaVIrus Disease 2019).³ The outbreak in Wuhan expanded quickly and led to the lockdown of Wuhan, the Hubei 60 61 province and other parts of China. While the lockdown, at least temporarily, brought the situation under 62 control in China, SARS-CoV-2 spread globally causing a pandemic with, so far, 1,700,000 infections and 107,000 fatalities (as of April 11th, 2020). 63

Nucleic acid tests that detect the SARS-CoV-2 RNA genome were quickly developed and are now widely 64 employed to diagnose COVID19 disease.^{4,5} However, there remains a great need for laboratory assays 65 that measure antibody responses and determine seroconversion. While such serological assays are not 66 67 well suited to detect acute infections, they support a number of highly relevant applications. First, 68 serological assays allow us to study the immune response(s) to SARS-CoV-2 in a qualitative and 69 quantitative manner. Second, serosurveys are needed to determine the precise rate of infection in an 70 affected area, which is an essential variable to accurately determine the infection fatality rate. Third, 71 serological assays will allow for the identification of individuals who mounted strong antibody responses 72 and who could serve as donors for the generation of convalescent serum therapeutics. Lastly, serological 73 assays will potentially permit to determine who is immune and who is not. This information may be very 74 useful for deploying immune healthcare workers in a strategic manner as to limit the risk of exposure 75 and inadvertent spread of the virus. It could also allow a certain proportion of the population that has 76 already acquired immunity to go back to 'normal life'. Of course, parallel studies that determine which 77 antibody titers correlate with protection are needed to support these potential measures.

Sarbecoviruses express a large (approximately 140 kDa) glycoprotein termed spike protein (S, a homotrimer), which mediates binding to host cells via interactions with the human receptor angiotensin converting enzyme 2 (ACE2).⁶⁻⁸ The S protein is very immunogenic with the receptor-binding domain (RBD) being the target of many neutralizing antibodies.⁹ Individuals infected with coronaviruses typically mount neutralizing antibodies, which might be associated with some level of protection for a period of months to years¹⁰⁻¹², and a neutralizing response has been demonstrated for SARS-CoV-2 in an individual

case from day 9 onwards.¹³ Serum neutralization can be measured using replication competent virus but 84 the process requires several days and must be conducted in biosafety level 3 laboratory containment for 85 86 SARS-CoV-2. Potentially, pseudotyped viral particle based entry assays using lentiviruses or vesicular 87 stomatitis virus could be used but these reagents are not trivial to produce. A simple solution is the use 88 of a binding assay, e.g. an enzyme linked immunosorbent assays (ELISA), with recombinant antigen as 89 substrate. Here we report the development of such an assay and provide a protocol for both recombinant antigen production as well as the ELISA methodology.¹⁴ An assay based on our protocol 90 91 was implemented at Mount Sinai's clinical laboratory, has received emergency use authorization from New York State and is used for screening plasma donors with high titers of antibodies to SARS-CoV-2. 92 93 We have also distributed our protocol and reagents to well above 200 laboratories across the globe.

94

95 Results

96 Expression constructs and generation of recombinant SARS-CoV-2 proteins

97 We generated two different versions of the SARS-CoV-2 spike protein. The first construct expresses a full 98 length trimeric and stabilized version of the spike protein and the second one produces only the much 99 smaller receptor binding domain (RBD). The sequence used for both proteins is based on the genomic sequence of the first virus isolate, Wuhan-Hu-1, which was released on January 10th 2020.¹ Sequences 100 were codon optimized for mammalian cell expression. The full-length spike protein sequence was 101 102 modified to remove the polybasic cleavage site, which is recognized by furin and to add a pair of stabilizing mutations (Figure 1).^{7,15,16} These two modifications were included to enhance the stability of 103 the protein based on published literature.^{7,15} At amino acid P1213 the sequence was fused to a thrombin 104 cleavage site, a T4 foldon sequence for proper trimerization and a C-terminal hexahistidine tag for 105 purification (Figure 1).^{17,18} The sequence was cloned into a pCAGGS vector for expression in mammalian 106 107 cells and into a modified pFastBac Dual vector for generation of baculoviruses and expression in insect cells. For expression of the RBD, the natural N-terminal signal peptide of S was fused to the RBD 108 109 sequence (amino acid 319 to 541) and joined with a C-terminal hexahistidine tag.¹⁹ The same vectors as 110 for the full length S protein were used to express the RBD. In mammalian cells, the RBD domain gave 111 outstanding yields (approximately 25-50 mg/liter culture), but expression was lower in insect cells 112 (approximately 1.5 mg/liter culture). Clear single bands were visible when the recombinant RBD proteins 113 were analyzed on a reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 114 with the insect cell derived protein (iRBD) running slightly lower than the mammalian cell derived 115 protein (mRBD) (Figure 1). The size difference likely reflects differences in glycan sizes between insect 116 cells and mammalian cells. The full-length S protein was also expressed in both systems with slightly 117 higher yields in mammalian cells (mSpike) than in insect cells (iSpike) (approximately 5 mg/liter cultures 118 versus 0.5 mg/liter culture). The full-length protein appeared as prominent band between 135 and 190 119 kDa followed by a faint, second band slightly below on a reducing SDS-PAGE, the higher species likely 120 being the full-length protein and the slightly lower species likely a cleavage product.

121

122 ELISA development

Initially, we tested a panel of 50 (59 for mRBD) banked human serum samples collected from study participants without and with confirmed previous viral infections (e.g., hantavirus, dengue virus, coronavirus NL63 – sample take 30 days post symptom onset) to establish an ELISA with our proteins. These human sera were used to test the background reactivity to the SARS-CoV-2 spike in the general US population covering an age range from approximately 20 to 65+ years. An initial set of four plasma/serum samples from three COVID19 survivors were used to determine the reactivity of SARS-CoV-2 infected individuals to the RBD and the full length spike (Figure 2).

130 ELISAs were performed by doing serial dilution of the individual serum samples. Values from the dilution 131 curves were used to determine the area under the curve (AUC), which was graphed. All COVID19 132 plasma/serum samples reacted strongly to both RBD and full-length spike protein while reactivity of the 133 other serum samples only yielded background reactivity (Figure 2). Reactivity of COVID19 sera was, in 134 general, stronger against the full-length S protein than against the RBD, likely reflecting the higher 135 number of epitopes found on the much larger spike protein. For the RBD the difference between 136 control sera and convalescent sera was larger when the mammalian cell derived protein was used as 137 compared to the insect cell derived RBD. The same was true for the full-length spike protein. Due to the 138 expanding epidemic in New York City, we tested next an additional 14 serum samples from patients with 139 acute COVID19 disease as well as convalescent participants for reactivity to mRBD and mSpike. These additional data were added to Figure 2B, 2D, 2F and 2H. All 14 samples reacted well with both RBD and 140 141 spike protein. Thus, our assays allowed to clearly distinguish the sera from participants diagnosed with 142 COVID19 from those collected prior to the pandemic (e.g., collected in the fall of 2019).

143 Our initial set of negative controls included convalescent serum from a participant with a confirmed 144 NL63 infection. Importantly, this sample did not produce a signal against the SARS-CoV-2 RBD or spike 145 underscoring the specificity of our assays. Since human coronaviruses OC43, 229E, NL63 and/or HKU1 146 are responsible for a large proportion of common colds every year, cross-reactivity between SARS-CoV-2 147 and these seasonal coronaviruses is of particular importance and warranted further investigation. To 148 test how common antibodies to human corona viruses other than SARS-CoV are in our "pre-pandemic 149 serum panel", we performed ELISAs coated with spike protein of coronavirus 229E and NL63. While 150 none of the negative control sera reacted to SARS-CoV-2 RBD and spike, the majority of samples yielded 151 strong signals to the spike proteins of these two human coronaviruses (Figure 2I and 2J). In addition, we 152 tested 21 different batches (27 vials) of pools of different products of normal human immune globulin 153 (NHIG), intended for intravenous use and derived from >1000 donors each. None of the NHIG 154 preparations reacted with SARS-CoV-2 RBD or spike protein and the signal obtained was similar to that 155 of the three irrelevant human monoclonal antibodies (mAbs). The RBD-binding mAb CR3022 produced, in contrast, a strong signal (Figure 3A and 3B).²⁰⁻²² Lastly, we tested panel of fifty plasma samples 156 157 collected from HIV positive patients banked 2008 and 2011. Again, none of the samples reacted with the 158 SARS-CoV-2 RBD or spike (Figure 3C and 3D).

159 The assay can measure antibodies in serum and plasma as well as with and without heat inactivation

160 One complexity with measuring antibodies in bodily fluids of COVID19 patients is, that infectious virus 161 could be present in the biospecimen, especially early during acute infection. One precaution that is, 162 therefore, often used to limit this risk is to heat inactivate serum or plasma for 1 hour at 56°C. To test if 163 such a heat treatment has an effect on detecting antibodies to the SARS-CoV2 RBD and spike, we 164 compared reactivity of matched non-treated and heat-treated serum samples. While slight differences

were observed, they were minimal suggesting that heat treatment has no negative impact on assay performance (Figure 4A and B). Similarly, we tested matched serum and plasma samples from patients with COVID19 and found negligible differences suggesting that both types of specimens can be used in

168 the assay interchangeably (Figure 4C and D).

169 Antibody isotyping, subtyping and neutralizing activity

For the four COVID19 patient plasma/sera from our initial panel, we performed an isotyping and subtyping ELISA using the mammalian cell expressed S proteins. Strong reactivity was found for all samples for IgG3, IgM and IgA (**Figure 5A**). An IgG1 signal was detected for the majority of samples; low reactivity for IgG2 (in five samples) and IgG4 (in four samples) was also detected. Data from this isotyping ELISA suggest that the IgG response is dominated by IgG3 subtype. Furthermore, we correlated the ELISA reactivity with the neutralizing activity of sera against the USA-WA1/2020 isolate. ELISA titers and microneutralization titers correlated significantly (**Figure 5B**) with a Spearman r of 0.9279.

177

178 Discussion

179 Here we describe a serological method to detect seroconversion upon SARS-CoV-2 infection with high 180 specificity and sensitivity. The method is based on reactivity to the immunogenic S protein of the virus. 181 The method is relatively simple and quick in its execution and can be performed at biosafety level 2 level 182 as it does not involve live virus. We have tested these methods using banked serum samples and NHIG 183 preparations obtained from individuals before SARS-CoV-2 started to widely circulate in the US. These 184 serum samples produced low, close to baseline signals in our ELISAs. The age range of the participants 185 was broad, ranging from 20 to 65+ years of age and it is likely that most of these individuals had 186 experienced infections with human coronaviruses including the alphacoronaviruses NL63 and 229E as 187 well as the betacoronaviruses OC43 and HKU1. In fact, the majority of our negative control subjects had strong reactivity to the spike of NL63 and 229E (but showed no cross-reactivity to SARS-CoV-2 RBD and 188 189 spike). We also included paired serum samples (acute and convalescent) from a participant with a laboratory confirmed coronavirus NL63 infection. Our data show that there is no or only negligible cross-190 191 reactivity from human coronaviruses to SARS-CoV-2. Of note, even infection with the human alphacoronavirus NL63, which also uses ACE2 as receptor²³, did not induce cross-reactivity. Similar 192 findings were reported in a recent preprint where sera from negative control subjects reacted well with 193 spike proteins from human coronavirus but not with SARS-CoV-2.²⁴ This is of great importance because 194 it suggests that humans are completely naïve to SARS-CoV-2, which may explain the relatively high R_0 of 195 SARS-CoV-2 compared to other respiratory viruses such as influenza virus.²⁵ It might also suggest that 196 antibody-dependent enhancement from human coronavirus induced cross-reactive antibodies targeted 197 at the S protein is unlikely to be the cause of the high pathogenicity of the virus in humans.²⁶ 198

Our data show strong seroconversion after natural infection with SARS-CoV-2. Results from our assays suggest that antibodies mounted upon infection target the full length S protein as well as the RBD, which is the major target for neutralizing antibodies for related viruses coronaviruses.⁹ In fact, sample SARS-CoV2 #1 was tested in another study in neutralization assays and showed a neutralizing titer of 1:160.¹³ In addition, we performed microneutralization assays with a subset of our samples and found excellent correlation between our ELISA titers against the spike protein and virus neutralization. Several of the sera from individuals with confirmed COVID19 showed very strong neutralizing activity with 50%

206 inhibitory concentrations in the hundreds and thousands. Thus, seroconversion might lead to protection 207 from reinfection. Of course, protection – and antibody titers correlated with protection – need to be 208 determined in the near future. In fact, studies to determine whether antibody titers correlate with 209 protection from COVID19 should be one of the highest research priorities at this time. Of note, the ELISA 210 reagents used are derived from the original sequence from Wuhan, the neutralization assays were performed with USA-WA1/2020 (an Asian lineage strain) while the majority of sera were obtained from 211 subjects infected with European-lineage viruses.²⁷ The observed correlation between ELISA and 212 213 neutralization assays hints at minimal antigenic changes. Another interesting finding was, that the IgG3 214 response appeared stronger than the IgG1 response which is in contrast to e.g. the immune response to influenza where usually IgG1 responses dominate.^{28,29} This is of interest since IgG3 has a stronger affinity 215 to activating Fc-receptors but a shorter half-life than IgG1. We also detected strong IgA and IgM 216 217 responses in the blood compartment. Of note, level of reactivity and antibody isotypes closely matched 218 expected patterns based on time since symptom onset very well. Antibody isotype and subtype titers were determined using specific secondary antibodies and future studies; however, need to confirm this 219 220 finding using independent methods.

221 We also evaluated if heat inactivation can interfere with detection of antibodies. Heat inactivation at 222 56°C is a standard precaution for work with human sera in many laboratories. A recent pre-print had shown that a commercial AIE/quantum dot-based fluorescence immunochromatographic assay (AFIA, 223 224 KingFocus Biomedical Engineering Co.,Ltd) assays failed to detect antibodies in samples treated at 56°C 225 for 30 min.³⁰ We had made similar observations with a lateral flow assay from BioMedomics. However, our assay was able to detect a signal in samples heat treated for 60 min at 56°C comparable to a signal 226 227 obtained from non-heat treated sera. Similarly, we found that matched serum and plasma samples 228 showed similar reactivity in the ELISA making it very versatile in terms of which type of specimen can be 229 used.

230 We did not formally assess specificity and sensitivity of our assay since it might be implemented with 231 different readouts (e.g. OD at a certain dilution, AUC, endpoint titer etc.) and since the assay itself will 232 slightly vary depending on the laboratory that will implement it. However, it is clear from our data that 233 the assay has a high specificity and sensitivity. In addition, our assays are able to measure a quantitative 234 titer which correlates well with neutralization of virus. This is in contrast to many commercial assays that 235 have recently become available on the market which deliver only a qualitative result. Of note, many of 236 these assays have not been independently validated and some of them have been shown to be unfit for 237 the purpose of specifically detecting seroconversion after SARS-CoV-2 infections (e.g. in the UK; Loredo, 238 Texas etc.).

239 We believe that our ELISA method will be key for serosurveys aimed at determining the real attack rate 240 and infection fatality rate in different human populations and to map the kinetics of the antibody 241 response to SARS-CoV-2. While we found seroconversion in severe, mild and asymptomatic cases, it is 242 possible that some individuals do not seroconvert or that antibody titers wane within short periods of 243 time. To be able to interpret serosurveys correctly, studies to assess the kinetics of the antibody 244 response and the rate of non-responders are urgently needed. Clinical trials with convalescent serum as therapeutic have been initiated in China (e.g. NCT04264858). In addition, a recent report suggests that 245 compassionate use of these interventions could be successful.³¹ Screening potential plasma donors for 246 247 high antibody titers using our assay is faster and easier than performing standard neutralization assays 248 in BSL3 containment laboratories. Our assay has already been implemented for this purpose in Mount

249 Sinai's Clinical Laboratory Improvement Amendments (CLIA) regulated clinical laboratory and has 250 received emergency use authorization from New York State. Indeed, more than 20 patients with 251 COVID19 have been compassionately treated at Mount Sinai Hospital with antibody rich plasma from 252 convalescent donors identified with our assays. Last but not least, we believe that our assays could be 253 used to screen health care workers to allow selective deployment of immune medical personnel to care 254 for patients with COVID19. Such a strategy would likely limit nosocomial spread of the virus. More 255 generally, individuals with strong antibody responses could return to normal life, something that might 256 be especially important if a second or third pandemic wave makes quarantine measures again 257 necessary. Importantly, the assumption that individuals with antibodies to the SARS-CoV-2 confer 258 protection from reinfection needs to be confirmed and studies to investigate this should be started as 259 soon as possible. Of course, the generated recombinant proteins are also excellent reagents for vaccine 260 development and can serve as baits for sorting B cells for monoclonal antibody generation. We are making the methods and laboratory reagents widely available to the research community in order to 261 support the global effort to limit and mitigate spread of SARS-CoV-2. A detailed protocol¹⁴ for antigen 262 263 expression and ELISA set up is available from the corresponding author and plasmids and proteins have 264 so far been shared with more than 200 laboratories worldwide and also deposited at BEI Resources.

265

266 Methods

267 Recombinant proteins

268 The mammalian cell codon optimized nucleotide sequence coding for the spike protein of SARS-CoV-2 isolate (GenBank: MN908947.3) was synthesized commercially (GeneWiz). The receptor binding domain 269 270 (RBD, amino acid 319 to 541, RVQP....CVNF) along with the signal peptide (amino acid 1-14, 271 MFVF....TSGS) plus a hexahistidine tag was cloned into mammalian expression vector pCAGGS as well as 272 in a modified pFastBacDual vectors for expression in baculovirus system. The soluble version of the spike 273 protein (amino acids 1-1213, MFVF....IKWP) including a C-terminal thrombin cleavage site, T4 foldon 274 trimerization domain and hexahistidine tag was also cloned into pCAGGS. The protein sequence was 275 modified to remove the polybasic cleavage site (RRAR to A) and two stabilizing mutations were 276 introduced as well (K986P and V987P, wild type numbering). Recombinant proteins were produced using the well-established baculovirus expression system and this system has been published in great 277 278 detail in ^{17,32,33} including a video guide. Recombinant proteins were also produced in Expi293F cells 279 (ThermoFisher) by transfections of these cells with purified DNA using ExpiFectamine 293 Transfection 280 Kit (ThermoFisher). Supernatants from transfected cells were harvested on day 3 post-transfection by 281 centrifugation of the culture at 4000 g for 20 minutes. Supernatant was then incubated with 6 mls Ni-282 NTA agarose (Qiagen) for 1-2 hours at room temperature. Next, gravity flow columns were used to 283 collect the Ni-NTA agarose and the protein was eluted. Each protein was concentrated in Amicon 284 centrifugal units (EMD Millipore) and re-suspended in phosphate buffered saline (PBS). Proteins were 285 analyzed on reducing SDS-PAGE. The DNA sequence for all constructs is available from the Krammer 286 laboratory. Several of the expression plasmids and proteins have also been submitted to BEI Resources 287 and can be requested from their web page for free (https://www.beiresources.org/). S1 proteins of NL63 and 229E were obtained from Sino Biologics (produced in 293HEK cells, hexa-histidine tagged). A 288 289 detailed protocol for protein expression of RBD and spike in mammalian cells is also available.¹⁴

290

291 SDS-PAGE

292 Recombinant proteins were analyzed via a standard SDS-PAGE gel to check protein integrity. One ug of

protein was mixed with 2X Laemmli buffer containing 5% beta-mercaptoethanol (BME) at a ratio of 1:1.

Samples were heated at 100 °Celsius for 15 minutes and then loaded onto a polyacrylamide gel (5% to

20% gradient; Bio-Rad). Gels were stained with SimplyBlue SafeStain (Invitrogen) for 1-2 hours and then

- 296 de-stained in distilled water overnight.
- 297
- 298 Human samples
- Human plasma and serum samples were obtained from a number of different sources.
- First, de-identified samples from the University of Melbourne (n=3, taken on day 2, 4 and 6 after symptom onset) and University of Helsinki (n=1, day 20 after symptom onset, neutralizing titers 1:160)¹³
- 302 were used as positive controls. For those, human experimental work was conducted according to the
- 303 Declaration of Helsinki Principles and according to the Australian National Health and Medical Research 304 Council Code of Practice. All participants provided written informed consent prior to the study. The
- studies were approved by the Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1,
 1955465.2) Human Research Ethics Committees, and under research permit for project TYH2018322 of
- 307 Helsinki University Hospital Laboratory.
- 308 Second, banked human samples were collected from study participants enrolled in several ongoing IRB
- approved longitudinal observational study protocols of the Mount Sinai Personalized Virology Initiative.
 The pre-pandemic serum panel comprised samples selected based on the date of collection (e.g., fall
- 311 2019) and whether participants had a documented history of viral infection (e.g., dengue virus,
- hantavirus, Chikungunya virus, coronavirus NL63). All participants agreed to sample banking and future research use. Self-reported ethnicities of the individuals from which samples were tested included
- 314 Caucasian, Asian, African American and Hispanic. Samples included sera from a participant with acute
- 315 NL63 infection as determined by the Biofire Respiratory panel. We included serum collected at day 3
- post symptom onset as well as convalescent serum from the same person (day 30 post symptom onset).
- 317 These samples served as negative controls given that they were collect prior to SARS-CoV-2 spread in
- the US. Six subjects were 20-29, 19 were 30-39, 13 were 40-49, 7 were 50-59 years old and six were 60
- or older. For the mRBD ELISAs sera from additional nine subjects were tested (30-39: 2; 40-49: 4; 50-59: 2; 60+: 1). The pre-pandemic panel was complemented by a collection of plasma samples collected from
- 321 50 HIV-1 infected individuals between 2008 and 2011.
- The COVID19 panel comprised serum and plasma samples from individuals with severe, mild or asymptomatic SARS-CoV-2 infections. Seven paired serum and plasma samples from patients with COVID19 were used for comparison purposes. These samples were collected between 7 and 31 days post symptom onset.
- 326

327 Normal human immunoglobulin (NHIG)

The following NHIG preparations, each prepared from >1000 blood/ plasma donors and intended for intravenous use for medical conditions, were tested in an ELISA to determine if they have reactivity against SARS-CoV-2 spike or RBD: Octagam (M934A8541), Gamunex-c (B2GMD00943, A1GLD01882, B3GLD01223, A1GLD01902, B2GLD01972, B3GGD00143, A1GKE00012 (2 different vials), B2GKD00863, B2GJE00033 (3 different vials)), Gammagard liquid (LE12T292AB, LE12V238AB, LE12V278AD), Gammagard S/D (LE08V027AB, 4 different vials), Gammagard liquid (C19G080AAA, LE12V071AD, LE12V230AB, LE12V115AC, LE12V205AB, LE12VE25AB, LE12V115AC).

335

336 ELISA

The ELISA protocol was adapted from previously established protocols ^{34,35}. Ninety-six well plates (Immulon 4 HBX; Thermo Scientific) were coated overnight at 4°Celsius with 50 ul per well of a 2 ug/ml

339 solution of each respective protein suspended in PBS (Gibco). The next morning, the coating solution

340 was removed and 100 ul per well of 3% non-fat milk prepared in PBS with 0.1% Tween 20 (TPBS) was 341 added to the plates at room temperature (RT) for 1 hour as blocking solution. Serum samples were 342 heated at 56°C for 1 hour before use to reduce risk from any potential residual virus in serum. Serial 343 dilutions of serum and antibody samples were prepared in 1% non-fat milk prepared in TPBS. The 344 blocking solution was removed and 100 ul of each serial dilution was added to the plates for 2 hours at 345 RT. Next, the plates were washed thrice with 250ul per well of 0.1% TPBS. Next, a 1:3000 dilution of goat 346 anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (ThermoFisher 347 Scientific) was prepared in 0.1% TPBS and 100 ul of this secondary antibody was added to each well for 1 348 hour. Plates were again washed thrice with 0.1% TBS. Once completely dry, 100 ul of SigmaFast OPD (o-349 phenylenediamine dihydrochloride; Sigma-Aldrich) solution was added to each well. This substrate was 350 left on the plates for 10 minutes and then the reaction was stopped by addition of 50 μ L per well of 3 M 351 hydrochloric acid (HCI). The optical density at 490 nanometers was measured via a Synergy 4 (BioTek) 352 plate reader. The background value was set at and optical density (OD) 490nm of 0.11 and area under 353 the curve (AUC) was calculated. AUC values below 1 were assigned a value of 0.5 for graphing and 354 calculation purposes. Data were analyzed using Prism 7 (Graphpad). In some cases endpoint titers were 355 calculated, the endpoint titer being the last dilution before reactivity dropped below and OD 490nm of 356 below 0.11. To determine the impact of heat treatments, paired samples that were heat treated or not 357 treated were analyzed. NHIGs were run similar as serum/plasma samples but with a starting dilution at a concentration of 100 ug/ml. Three non-SARS-CoV-2 reactive human mAbs and CR3022²⁰⁻²², a human 358 359 mAb reactive to the RBD of both SARS-CoV-1 and SARS-CoV-2 were used as controls.

To assess the distribution of the different antibody isotypes/subclasses in the samples that reacted well in our standard ELISA, another ELISA was performed with different secondary antibodies ²⁹. These antibodies include anti-human IgA (α -chain-specific) HRP antibody (Sigma A0295) (1:3,000), anti-human IgM (μ -chain-specific) HRP antibody (Sigma A6907) (1:3,000), anti-human IgG1 Fc-HRP (Southern Biotech 9054-05) (1:3,000), anti-human IgG2 Fc-HRP (Southern Biotech #9060-05) (1:3,000), anti-human IgG3hinge-HRP (Southern Biotech 9210-05) (1:3,000), and anti-human IgG4 Fc-HRP (Southern Biotech 9200-05).

367

368 Microneutralization assay

369 Vero.E6 cells were seeded at a density of 20,000 cells per well in a 96-well cell culture plate in cDMEM. 370 The following day, heat inactivated serum samples (dilution of 1:10) were serially diluted 3-fold in 2X 371 MEM (20% 10× minimal essential medium (Gibco), 42mM L-glutamine, 0.2% of sodium bicarbonate 372 [wt/vol; Gibco], 202mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco), 2002U/ml 373 penicillin–2002µ/ml streptomycin (Gibco), and 0.4% bovine serum albumin (MP Biomedical)). The 374 authentic SARS-CoV-2 virus (USA-WA1/2020, GenBank: MT020880) was diluted to a concentration of 375 100 50% cell culture infectious doses (TCID₅₀) in 2xMEM. Eighty μ L of each serum dilution and 80 μ L of the virus dilution were added to a 96-well cell culture plate and allowed to incubate for 1 hr at room 376 377 temperature. cDMEM was removed from Vero.E6 cells and 120 µL of the virus-serum mixture was added to the cells and the cells were incubated at 37°C for 1 hr. After the 1 hr incubation, the virus-378 379 serum mixture was removed from the cells and 100 μ L of each corresponding serum dilution and 100 μ L 380 of 2X MEM containing 2% FBS (Corning) was added to the cells. The cells were incubated for 48 hr at 381 37°C and then fixed with 10% paraformaldehyde (PFA) (Polysciences, Inc) for 24 hr at 4°C. Following fixation, the PFA was removed and the cells were washed with 200 μ L of PBS. The cells were then 382 383 permeabilized by the addition of 150 µL of PBS containing 0.1% Triton X-100 for 15 minutes at room temperature. The plates were then washed three times with PBS containing 0.1% Tween 20 (PBS-T) and 384 385 blocked in blocking solution (3% milk [American Bio] in PBS-T) for 12h at room temperature. After

386 blocking, 100 µL of 1C7 (anti-SARS NP antibody generated in house) at a dilution of 1:1000 was added to 387 all wells and the plates were allowed to incubate for 1 hr at room temperature. Plates were then 388 washed three times with PBS-T before the addition of goat anti-mouse IgG-horseradish peroxidase (IgG-389 HRP; Rockland Immunochemicals) (diluted 1:3000) in blocking solution for 12hr at room temperature. 390 Plates were then washed three times with PBS-T and the O-phenylenediamine dihydrochloride (OPD) 391 substrate (SigmaFast OPD; Sigma-Aldrich) was added. After a 10-minute room temperature incubation, 392 the reaction was stopped by adding 50 $\mathbb{Z}\mu$ L of 3 $\mathbb{Z}M$ HCl to the mixture. The optical density (OD) was 393 measured at 4902nm on a Synergy 4 plate reader (BioTek). A cutoff value of the average of the OD 394 values of blank wells plus three standard deviations was established for each plate and used for 395 calculating the microneutralization titer.

396

397 Statistical analysis

398 Differences between negative controls and positive controls were analyzed using an unpaired t-test.

399 Differences between paired non-treated and heat-treated samples as well as paired serum and plasma

- 400 samples were analyzed using a paired t-test. Correlation between ELISA titers and neutralization titers
- 401 were analyzed using Spearman's rank test. Analyses were performed in GraphPad Prism.
- 402

403 Acknowledgements

404 We would like to thank Yong-Zhen Zhang (Fudan University) and Eddie Holmes (University of Sydney) for 405 sharing the sequence of the first SARS-CoV-2 isolate in a very timely manner. We thank Jill Garlick and 406 Janine Roney (Alfred Hospital, Melbourne) for data and specimen collection and Nouran Aboelregal for 407 making lots of different NHIGs products (Mount Sinai) available. We are also thankful to Genewiz for 408 speeding up gene synthesis for this project, and being very accommodating to our needs. Furthermore, 409 we want to thank Donna Tidmore for help with ordering primers with near light speed and and finally 410 Susie (Changsu) Dong for commuting to New Jersey on several occasions to pick up reagents from 411 Genewiz. We also thank the study participants for providing biospecimen for research purposes and the 412 Conduits: Mount Sinai Health System Translational Science Hub (NIH grant U54TR001433) for supporting 413 sample collection. The work of the Personalized Virology Initiative is supported by institutional funds 414 and philanthropic donations. This work was partially supported by the NIAID Centers of Excellence for 415 Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C, the Australian National 416 Health and Medical Research Council (NHMRC) NHMRC Program Grant (1071916) and NHMRC Research 417 Fellowship Level B (#1102792), the Academy of Finland and Helsinki University Hospital Funds 418 (TYH2018322). Furthermore, we thank our generous community for providing essential funds and 419 support for our SARS-CoV-2 and COVID-19 research efforts. The following reagent was deposited by the 420 Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-421 Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. Finally, we want to thank all the study 422 participants for their contribution to research. We wish the patients with COVID19 a speedy recovery.

- 423 Data availability statement
- 424 The data shown in the manuscript is available upon request from the corresponding author.
- 425 **Conflict of interest**

426 Mount Sinai is in the process of licensing out assays based on the assays described here to commercial 427 entities.

428

429 References

430 1. Wu, F., et al. A new coronavirus associated with human respiratory disease in China. Nature 431 (2020).432 2. Zhou, P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. 433 Nature (2020). 434 3. Gorbalenya, A.E., et al. The species Severe acute respiratory syndrome-related coronavirus: 435 classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology (2020). 436 Chu, D.K.W., et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak 4. 437 of Pneumonia. Clin Chem (2020). 438 5. Corman, V.M., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro 439 Surveill 25(2020). 440 6. Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for 441 SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol (2020). 442 7. Wrapp, D., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. 443 Science (2020). 444 Walls, A.C., et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. 8. 445 Cell (2020). 446 9. Berry, J.D., et al. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of 447 repertoire, antigen structure or mAb technology. MAbs 2, 53-66 (2010). 448 10. Liu, W., et al. Two-year prospective study of the humoral immune response of patients with 449 severe acute respiratory syndrome. J Infect Dis 193, 792-795 (2006). 450 11. Callow, K.A., Parry, H.F., Sergeant, M. & Tyrrell, D.A. The time course of the immune response to 451 experimental coronavirus infection of man. *Epidemiol Infect* **105**, 435-446 (1990). 452 Choe, P.G., et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 12. 453 2015. Emerg Infect Dis 23, 1079-1084 (2017). 454 13. Haveri, A., et al. Serological and molecular findings during SARS-CoV-2 infection: the first case 455 study in Finland, January to February 2020. (Eurosurveillance, 2020). 456 14. Stadlbauer, D., et al. A detailed protocol for a serological assay to detect SARS-CoV-2 457 seroconversion in humans: antigen production and test setup. (submitted). 458 15. Pallesen, J., et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV 459 spike antigen. Proc Natl Acad Sci U S A 114, E7348-E7357 (2017). 460 16. Kirchdoerfer, R.N., et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 461 118-121 (2016). 462 17. Krammer, F., et al. A carboxy-terminal trimerization domain stabilizes conformational epitopes 463 on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7, e43603 464 (2012). 465 18. Margine, I., Palese, P. & Krammer, F. Expression of Functional Recombinant Hemagglutinin and 466 Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression 467 System. J Vis Exp (2013). Li, F., Li, W., Farzan, M. & Harrison, S.C. Structure of SARS coronavirus spike receptor-binding 468 19. 469 domain complexed with receptor. Science 309, 1864-1868 (2005). 470 20. Tian, X., et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-471 specific human monoclonal antibody. Emerg Microbes Infect 9, 382-385 (2020).

472	21.	ter Meulen, J., et al. Human monoclonal antibody combination against SARS coronavirus:
473		synergy and coverage of escape mutants. <i>PLoS Med</i> 3 , e237 (2006).
474	22.	Yuan, M., et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-
475		2 and SARS-CoV. Science (2020).
476	23.	Wu, K., Li, W., Peng, G. & Li, F. Crystal structure of NL63 respiratory coronavirus receptor-
477		binding domain complexed with its human receptor. Proc Natl Acad Sci U S A 106, 19970-19974
478		(2009).
479	24.	Khan, S., et al. Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses
480		and SARS-CoV-2 Using Coronavirus Antigen Microarray. <i>bioRxiv</i> , 2020.2003.2024.006544 (2020).
481	25.	Li, Q., et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected
482		Pneumonia. <i>N Engl J Med</i> (2020).
483	26.	Tseng, C.T., et al. Immunization with SARS coronavirus vaccines leads to pulmonary
484		immunopathology on challenge with the SARS virus. <i>PLoS One</i> 7 , e35421 (2012).
485	27.	Gonzalez-Reiche, A.S., et al. Introductions and early spread of SARS-CoV-2 in the New York City
486		area. <i>medRxiv</i> , 2020.2004.2008.20056929 (2020).
487	28.	Nachbagauer, R., et al. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin
488		Stalk-Reactive Antibodies in Humans. <i>MBio</i> 7 (2016).
489	29.	Rajendran, M., et al. Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children,
490		Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin. mBio
491		8 (2017).
492	30.	Hu, X., et al. Heat inactivation of serum interferes with the immunoanalysis of antibodies to
493		SARS-CoV-2. <i>medRxiv</i> , 2020.2003.2012.20034231 (2020).
494	31.	Shen, C., et al. Treatment of 5 Critically III Patients With COVID-19 With Convalescent Plasma.
495		JAMA (2020).
496	32.	Amanat, F., et al. Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New
497		World Arenaviruses. <i>mSphere</i> 3 (2018).
498	33.	Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and
499		neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression
500		system. <i>J Vis Exp</i> , e51112 (2013).
501	34.	Amanat, F., Meade, P., Strohmeier, S. & Krammer, F. Cross-reactive antibodies binding to H4
502		hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model.
503		Emerg Microbes Infect 8 , 155-168 (2019).
504	35.	Wohlbold, T.J., et al. Broadly protective murine monoclonal antibodies against influenza B virus
505		target highly conserved neuraminidase epitopes. <i>Nat Microbiol</i> 2 , 1415-1424 (2017).

506

507 Figure legends

508

Figure 1: Constructs for recombinant protein expression. A Visualization of the trimeric spike protein of 509 SARS-CoV-2 based on PBD # 6VXX using Pymol.⁸ One monomer is colored in dark blue while the 510 remaining two monomers are held in light blue. The receptor binding domain (RBD) of the dark blue 511 trimer is highlighted in red. B Schematic of the wild type full length spike protein with signal peptide, 512 ectodomain, receptor binding domain, furin cleavage site, S1, S2, and transmembrane and endodomain 513 domain indicated. C Schematic of the soluble trimeric spike. The polybasic/furin cleavage site (RRAR) 514 515 was replaced by a single A. The transmembrane and endodomain were replaced by a furin cleavage site, 516 a T4 foldon tetramerization domain and a hexahistidine tag. Introduction of K986P and V987P has been

517 shown to stabilize the trimer in the pre-fusion conformation. **D** Schematic of the soluble receptor 518 binding domain construct. All constructs are to scale. **E** Reducing SDS PAGE of insect cell and mammalian 519 cell derived soluble trimerized spike protein (iSpike and mSpike). **F** Reducing SDS PAGE of insect cell 520 derived and mammalian cell derived recombinant receptor binding domain (iRBD and mRBD).

521 Figure 2: Reactivity of control and SARS-CoV-2 convalescent sera to different spike antigens. A-D 522 Reactivity to insect cell derived RBD (iRBD), mammalian cell derived RBD (mRBD), insect cell derived 523 soluble spike protein (iSpike) and mammalian cell derived soluble spike protein (mSpike). Sera from 524 SARS-CoV-2 infected individuals are shown in red. One sample, shown in green, is a convalescent serum 525 sample post NL63 infection. E-F shows data from the same experiment but graphed as area under the 526 curve (AUC) to get a better quantitative impression. The n for the control samples is 50 except for the 527 iRBD where it is 59. Statistics were performed using an unpaired two-tailed student's t-test in Graphpad Prism. I-G shows reactivity of the 50 negative control samples from A-F against spike protein from 528 529 human coronaviruses 229E and NL63.

Figure 3: Figure 3: Human normal immunoglobulin preparations and historic sera from HIV+ patients do not react with the SAR-CoV-2 spike. A-B Reactivity of 21 different pools of human normal immunoglobulin (HNIG) preparations (27 different vials) to mRBD and mSpike of SARS-CoV-2. MAb CR3022 was used as positive control, three different irrelevant human mAbs were used as negative control. C-D shows reactivity of historic samples from 50 HIV+ individuals to mRBD and mSpike of SARS-CoV-2. Both HNIG and serum samples from HIV+ donors were collected before the SARS-CoV-2 pandemic.

Figure 4: Effect of heat treatment and serum versus plasma on assay performance. A-B Reactivity of
 paired non-treated serum and heat treated serum samples to mRBD and mSpike of SARS-CoV-2 (n=5). C D Reactivity of paired serum and plasma samples to mRBD and mSpike of SARS-CoV-2 (n=7). Statistics
 were performed using a paired student's t-test in Graphpad Prism.

Figure 5: Isotypes and subtypes of antibodies from COVID19 patients to the soluble spike protein and correlation between ELISA and microneutralization titer. (A) Mammalian cell derived spike protein was used to study isotype/subclass distribution of antibodies (n=13 positive samples). (B) Correlation between ELISA titers and microneutralization titers (n=12, the three samples from negative control sera overlap and are displayed as single point). Statistics were performed using Pearson's rank test in Graphpad Prism.









Α



B

Correlation